8-K filing — Inhibikase Therapeutics, Inc. (IKT)
Filed: 2026-08-26 AccNo: 0001193125-26-368296 Size: 150 KB Item 4.01: Changes in Registrant's Certifying Accountant Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Inhibikase Therapeutics Q2 EPS $(0.11), Inline
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 8:16 PM
- Checked
- Aug 11, 2026, 8:16 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Inhibikase Therapeutics Says FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-001, Prodrug Of Imatinib Mesylate, For Treatment Of PAH
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today announced
Read original at benzingaDanaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading. Other stocks also decline.
Read original at benzinga